Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NELIA ESTHER SANCHEZ-CRESPO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1790990851
CMS profile
699626
Location
HOLLYWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$252.44

16 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $252.44 16

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NELIA ESTHER SANCHEZ-CRESPO

NPI 1790990851 · CMS profile ID 699626

Allopathic & Osteopathic Physicians / Internal Medicine

HOLLYWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790990851?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NELIA ESTHER SANCHEZ-CRESPO, NPI 1790990851, CMS profile ID 699626. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790990851?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). NELIA ESTHER SANCHEZ-CRESPO, NPI 1790990851, CMS profile ID 699626. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790990851?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
NELIA ESTHER SANCHEZ-CRESPO, NPI 1790990851, CMS profile ID 699626, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1790990851?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

16 matching records · $252.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 16 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–16 of 16.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $24.4510/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811113163 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.7809/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763425646 CMS
Novartis Pharmaceuticals Corporation $17.4209/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813227533 CMS
PFIZER INC. $14.7707/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833381621 CMS
PFIZER INC. $17.6307/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832567061 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.1906/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763425648 CMS
AstraZeneca Pharmaceuticals LP $14.3305/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834352719 CMS
Lilly USA, LLC $15.9605/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818660999 CMS
Lilly USA, LLC $15.1804/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818614479 CMS
PFIZER INC. $19.8604/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833487705 CMS
Novartis Pharmaceuticals Corporation $16.2503/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813227529 CMS
Lilly USA, LLC $13.3303/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818665389 CMS
Lilly USA, LLC $13.2603/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818609677 CMS
Lilly USA, LLC $13.7102/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818609675 CMS
PFIZER INC. $13.8202/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833549405 CMS
Lilly USA, LLC $13.5001/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818669367 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $519.24 8
PY2020 $173.44 11
PY2021 $252.44 16
PY2022 $281.68 15
PY2023 $2,585.02 22
PY2024 $2,063.21 35
PY2025 $728.73 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,652,523.02 227
PY2024 Principal investigator $7,882,760.60 649
PY2023 Principal investigator $10,990,435.50 4,306
PY2022 Principal investigator $2,420,977.88 1,673
PY2021 Principal investigator $723,239.31 8
PY2020 Principal investigator $1,155,430.22 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

227 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $54,234.00 12/31/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFECT OF PF07293893 ON SKELETAL MUSCLE BIOMARKERS IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228743904
Principal investigator 1 PFIZER INC. $400,827.00 12/22/2025 Non-covered Recipient Entity
CenExel Hollywood FL
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF 28 WEEKS TO INVESTIGATE THE SAFETY AND EFFICACY OF ONCEWEEKLY MET097 IN ADULTS WITH OBESITY OR OVERWEIGHT FOLLOWED BY A 32WEEK EXTENSION VESPER1 No dispute reported 06/30/2026 1228721389
Principal investigator 1 ModernaTX, Inc. $520.00 12/15/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252985148
Principal investigator 1 ModernaTX, Inc. $1,500.00 12/11/2025 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985054
Principal investigator 1 SANOFI PASTEUR INC. $445.50 12/05/2025 Non-covered Recipient Entity
Research Centers Of America
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115596
Principal investigator 1 SANOFI PASTEUR INC. $29,601.00 12/01/2025 Non-covered Recipient Entity
Research Centers Of America
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115591
Principal investigator 1 ModernaTX, Inc. $66,330.00 11/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985070
Principal investigator 1 ModernaTX, Inc. $5,394.60 11/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985120
Principal investigator 1 ModernaTX, Inc. $3,199.50 11/27/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985188
Principal investigator 1 ModernaTX, Inc. $12,909.60 11/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985210
Principal investigator 1 ModernaTX, Inc. $1,472.00 11/20/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008554
Principal investigator 1 ModernaTX, Inc. $3,500.00 11/20/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008556
Principal investigator 1 ModernaTX, Inc. $1,900.00 11/20/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008566
Principal investigator 1 ModernaTX, Inc. $500.00 11/12/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985196
Principal investigator 1 SANOFI PASTEUR INC. $11,299.30 11/07/2025 Non-covered Recipient Entity
Research Centers Of America
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115573
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,263.00 11/06/2025 Non-covered Recipient Entity
Research Centers of America, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215509337
Principal investigator 1 Alnylam Pharmaceuticals Inc. $207.00 11/06/2025 Non-covered Recipient Entity
Research Centers of America, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215509343
Principal investigator 1 Alnylam Pharmaceuticals Inc. $854.00 11/06/2025 Non-covered Recipient Entity
Research Centers of America, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215509347
Principal investigator 1 Alnylam Pharmaceuticals Inc. $810.00 11/06/2025 Non-covered Recipient Entity
Research Centers of America, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215509351
Principal investigator 1 Alnylam Pharmaceuticals Inc. $518.00 11/06/2025 Non-covered Recipient Entity
Research Centers of America, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215509355
Principal investigator 1 Alnylam Pharmaceuticals Inc. $38.00 11/06/2025 Non-covered Recipient Entity
Research Centers of America, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215509359
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,835.00 11/06/2025 Non-covered Recipient Entity
Research Centers of America, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215509363
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,384.00 11/06/2025 Non-covered Recipient Entity
Research Centers of America, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215509366
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,110.00 11/06/2025 Non-covered Recipient Entity
Research Centers of America, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215509371
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,470.00 11/06/2025 Non-covered Recipient Entity
Research Centers of America, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215509375
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,654.00 11/06/2025 Non-covered Recipient Entity
Research Centers of America, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215509378
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,562.00 11/06/2025 Non-covered Recipient Entity
Research Centers of America, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215509382
Principal investigator 1 ModernaTX, Inc. $1,500.00 11/06/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985194
Principal investigator 1 ModernaTX, Inc. $500.00 11/06/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008540
Principal investigator 1 ModernaTX, Inc. $1,500.00 11/06/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008550
Principal investigator 1 ModernaTX, Inc. $3,120.00 10/29/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985106
Principal investigator 1 ModernaTX, Inc. $2,925.00 10/29/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985178
Principal investigator 1 ModernaTX, Inc. $5,850.00 10/29/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985206
Principal investigator 1 ModernaTX, Inc. $23,463.00 10/27/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985064
Principal investigator 1 ModernaTX, Inc. $10,189.80 10/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985132
Principal investigator 1 ModernaTX, Inc. $4,449.60 10/27/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985154
Principal investigator 1 ModernaTX, Inc. $10,692.00 10/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985160
Principal investigator 1 ModernaTX, Inc. $2,381.40 10/27/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985192
Principal investigator 1 ModernaTX, Inc. $1,500.00 10/27/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008560
Principal investigator 1 SANOFI PASTEUR INC. $375.00 10/27/2025 Non-covered Recipient Entity
Research Centers Of America
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115560
Principal investigator 1 SANOFI PASTEUR INC. $500.00 10/27/2025 Non-covered Recipient Entity
Research Centers Of America
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115584
Principal investigator 1 ModernaTX, Inc. $4,000.00 10/24/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252985090
Principal investigator 1 Alnylam Pharmaceuticals Inc. $12,566.00 10/23/2025 Non-covered Recipient Entity
Research Centers of America, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215509340
Principal investigator 1 SANOFI PASTEUR INC. $54,708.75 10/15/2025 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226095697
Principal investigator 1 PFIZER INC. $55,296.00 10/11/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 OPENLABEL 2PART STUDY TO ESTIMATE SEPARATELY THE EFFECT OF ITRACONAZOLE AND FOOD ON THE PHARMACOKINETICS OF PF07258669 IN OLDER ADULT OR HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228756549
Principal investigator 1 ModernaTX, Inc. $600.00 10/03/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008570
Principal investigator 1 ModernaTX, Inc. $5,694.30 09/29/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985128
Principal investigator 1 ModernaTX, Inc. $12,335.40 09/29/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985164
Principal investigator 1 PFIZER INC. $12,256.18 09/16/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228752215
Principal investigator 1 ModernaTX, Inc. $10,400.00 09/11/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252985092
Principal investigator 1 ModernaTX, Inc. $154.14 09/03/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985050
Principal investigator 1 ModernaTX, Inc. $194.40 09/03/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985098
Principal investigator 1 PFIZER INC. $35,188.16 09/03/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFECT OF PF07293893 ON SKELETAL MUSCLE BIOMARKERS IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228750016
Principal investigator 1 PFIZER INC. $9,232.64 09/03/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFECT OF PF07293893 ON SKELETAL MUSCLE BIOMARKERS IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228761378
Principal investigator 1 ModernaTX, Inc. $11,444.40 08/28/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985072
Principal investigator 1 ModernaTX, Inc. $21,278.70 08/28/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985122
Principal investigator 1 ModernaTX, Inc. $24,750.00 08/28/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985156
Principal investigator 1 ModernaTX, Inc. $650.70 08/28/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985170
Principal investigator 1 ModernaTX, Inc. $118.56 08/28/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008568
Principal investigator 1 ModernaTX, Inc. $3,250.00 08/20/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985094
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 08/15/2025 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215506533
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 08/15/2025 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215506537
Principal investigator 1 PFIZER INC. $16,964.15 08/14/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228767842
Principal investigator 1 ModernaTX, Inc. $260.00 07/28/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252985048
Principal investigator 1 ModernaTX, Inc. $1,340.00 07/28/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985088
Principal investigator 1 ModernaTX, Inc. $2,692.80 07/28/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985138
Principal investigator 1 ModernaTX, Inc. $599.40 07/28/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985176
Principal investigator 1 ModernaTX, Inc. $650.70 07/28/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985216
Principal investigator 1 ModernaTX, Inc. $54,340.00 07/28/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008538
Principal investigator 1 PFIZER INC. $14,845.35 07/25/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228772710
Principal investigator 1 ModernaTX, Inc. $324.00 07/23/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985058
Principal investigator 1 ModernaTX, Inc. $908.79 07/23/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985060
Principal investigator 1 ModernaTX, Inc. $388.80 07/23/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985062
Principal investigator 1 ModernaTX, Inc. $754.65 07/23/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985150
Principal investigator 1 ModernaTX, Inc. $517.14 07/23/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985152
Principal investigator 1 GlaxoSmithKline, LLC. $4,511.05 07/18/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES No dispute reported 06/30/2026 1192143911
Principal investigator 1 PFIZER INC. $1,979.38 07/16/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228764333
Principal investigator 1 Alnylam Pharmaceuticals Inc. $460.35 07/14/2025 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215506544
Principal investigator 1 Alnylam Pharmaceuticals Inc. $47.25 07/14/2025 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215506549
Principal investigator 1 Alnylam Pharmaceuticals Inc. $26,106.80 07/14/2025 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215506554
Principal investigator 1 PFIZER INC. $12,779.20 07/11/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 OPENLABEL 2PART STUDY TO ESTIMATE SEPARATELY THE EFFECT OF ITRACONAZOLE AND FOOD ON THE PHARMACOKINETICS OF PF07258669 IN OLDER ADULT OR HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228764345
Principal investigator 1 PFIZER INC. $5,605.20 07/11/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228772366
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17,450.90 07/02/2025 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215506540
Principal investigator 1 ModernaTX, Inc. $7,623.00 06/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985162
Principal investigator 1 ModernaTX, Inc. $28,710.00 06/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985174
Principal investigator 1 ModernaTX, Inc. $8,691.30 06/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985180
Principal investigator 1 PFIZER INC. $14,352.48 06/26/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228777323
Principal investigator 1 PFIZER INC. $33,067.09 06/26/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 OPENLABEL 2PART STUDY TO ESTIMATE SEPARATELY THE EFFECT OF ITRACONAZOLE AND FOOD ON THE PHARMACOKINETICS OF PF07258669 IN OLDER ADULT OR HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228790743
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,499.00 06/25/2025 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215506522
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 06/25/2025 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215506525
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 06/25/2025 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215506529
Principal investigator 1 ModernaTX, Inc. $7,265.96 06/18/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985052
Principal investigator 1 ModernaTX, Inc. $18,281.70 06/18/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985100
Principal investigator 1 ModernaTX, Inc. $42,570.00 06/18/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985108
Principal investigator 1 ModernaTX, Inc. $10,810.80 06/18/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985112
Principal investigator 1 ModernaTX, Inc. $8,532.00 06/18/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985190
Principal investigator 1 ModernaTX, Inc. $4,145.94 06/18/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008544
Principal investigator 1 PFIZER INC. $5,938.14 06/14/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228774836
Principal investigator 1 PFIZER INC. $13,700.00 06/11/2025 Non-covered Recipient Entity
CenExel Clinical Research INC
A PHASE 1 RANDOMIZED DOUBLEBLIND THIRDPARTYUNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS No dispute reported 06/30/2026 1228789878
Principal investigator 1 SANOFI PASTEUR INC. $70,762.20 06/11/2025 Non-covered Recipient Entity
Research Centers Of America
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226115564
Principal investigator 1 PFIZER INC. $267,212.75 05/30/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228762584
Principal investigator 1 ModernaTX, Inc. $20,379.60 05/28/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985102
Principal investigator 1 ModernaTX, Inc. $48,510.00 05/28/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985118
Principal investigator 1 ModernaTX, Inc. $8,454.60 05/28/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985168
Principal investigator 1 ModernaTX, Inc. $23,493.66 05/28/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008572
Principal investigator 1 PFIZER INC. $989.69 05/23/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228773242
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,500.00 05/22/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190308772
Principal investigator 1 PFIZER INC. $34,794.00 05/16/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 OPENLABEL 2PART STUDY TO ESTIMATE SEPARATELY THE EFFECT OF ITRACONAZOLE AND FOOD ON THE PHARMACOKINETICS OF PF07258669 IN OLDER ADULT OR HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228762933
Principal investigator 1 ModernaTX, Inc. $3,000.00 05/14/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985110
Principal investigator 1 ModernaTX, Inc. $875.00 05/14/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985124
Principal investigator 1 PFIZER INC. $12,930.97 05/14/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228763430
Principal investigator 1 PFIZER INC. $244.72 05/14/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228782058
Principal investigator 1 ModernaTX, Inc. $10,862.00 05/07/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985208
Principal investigator 1 PFIZER INC. $362.34 05/07/2025 Non-covered Recipient Entity
Research Centers of America LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228773926
Principal investigator 1 PFIZER INC. $599,761.54 05/06/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228773769
Principal investigator 1 SANOFI PASTEUR INC. $3,670.00 05/06/2025 Non-covered Recipient Entity
Research Centers Of America
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115534
Principal investigator 1 PFIZER INC. $128,453.75 04/29/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228796250
Principal investigator 1 ModernaTX, Inc. $7,365.60 04/28/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985074
Principal investigator 1 ModernaTX, Inc. $1,301.40 04/28/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985116
Principal investigator 1 ModernaTX, Inc. $48,551.40 04/28/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985200
Principal investigator 1 ModernaTX, Inc. $3,685.28 04/28/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008548
Principal investigator 1 ModernaTX, Inc. $3,043.04 04/28/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008562
Principal investigator 1 SANOFI PASTEUR INC. $24,960.96 04/28/2025 Non-covered Recipient Entity
Research Centers Of America
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115548
Principal investigator 1 PFIZER INC. $772.22 04/25/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 OPENLABEL 2PART STUDY TO ESTIMATE SEPARATELY THE EFFECT OF ITRACONAZOLE AND FOOD ON THE PHARMACOKINETICS OF PF07258669 IN OLDER ADULT OR HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228779628
Principal investigator 1 Mylan Technologies Inc. $230,210.50 04/22/2025 Non-covered Recipient Entity
Research Centers of America, LLC
A Phase 3, Multicenter, Open-Label, Single Arm Study of MR-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety No dispute reported 06/30/2026 1241759915
Principal investigator 1 ModernaTX, Inc. $36.50 04/17/2025 Non-covered Recipient Entity
Research Centers of America
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985096
Principal investigator 1 ModernaTX, Inc. $89.10 04/09/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985044
Principal investigator 1 ModernaTX, Inc. $154.14 04/09/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985142
Principal investigator 1 ModernaTX, Inc. $137.70 04/09/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985144
Principal investigator 1 ModernaTX, Inc. $388.80 04/09/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985184
Principal investigator 1 PFIZER INC. $5,168.00 04/08/2025 Non-covered Recipient Entity
Research Centers of America LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228778827
Principal investigator 1 PFIZER INC. $48,561.43 04/08/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228793692
Principal investigator 1 PFIZER INC. $9,152.75 04/05/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228781080
Principal investigator 1 ModernaTX, Inc. $99.78 04/04/2025 Non-covered Recipient Entity
Research Centers of America
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985198
Principal investigator 1 PFIZER INC. $6,691.97 03/28/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228789151
Principal investigator 1 ModernaTX, Inc. $3,151.80 03/24/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985068
Principal investigator 1 ModernaTX, Inc. $27,720.00 03/24/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985114
Principal investigator 1 ModernaTX, Inc. $7,048.80 03/24/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985136
Principal investigator 1 ModernaTX, Inc. $39,260.70 03/24/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985204
Principal investigator 1 ModernaTX, Inc. $11,516.50 03/24/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008534
Principal investigator 1 ModernaTX, Inc. $5,451.28 03/24/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008536
Principal investigator 1 PFIZER INC. $69,707.62 03/22/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228779888
Principal investigator 1 PFIZER INC. $12,050.00 03/22/2025 Non-covered Recipient Entity
Research Centers of America LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228783922
Principal investigator 1 PFIZER INC. $120,621.28 03/22/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228789697
Principal investigator 1 Novartis Pharmaceuticals Corporation $78,450.48 03/18/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190310486
Principal investigator 1 GlaxoSmithKline, LLC. $2,101.56 03/12/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES No dispute reported 06/30/2026 1192143906
Principal investigator 1 ModernaTX, Inc. $6,000.00 03/12/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of Modified mRNA Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985082
Principal investigator 1 ModernaTX, Inc. $6,360.00 03/12/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of Modified mRNA Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985140
Principal investigator 1 ModernaTX, Inc. $500.00 03/12/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of Modified mRNA Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985182
Principal investigator 1 ModernaTX, Inc. $2,000.00 03/12/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of Modified mRNA Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985218
Principal investigator 1 ModernaTX, Inc. $750.00 03/12/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of Modified mRNA Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985224
Principal investigator 1 ModernaTX, Inc. $8,000.00 03/12/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of Modified mRNA Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985226
Principal investigator 1 ModernaTX, Inc. $1,500.00 03/10/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of Modified mRNA Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985220
Principal investigator 1 ModernaTX, Inc. $1,000.00 03/10/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of Modified mRNA Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985222
Principal investigator 1 Mylan Technologies Inc. $235,499.50 03/06/2025 Non-covered Recipient Entity
Research Centers of America, LLC
A Phase 3, Multicenter, Open-Label, Single Arm Study of MR-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety No dispute reported 06/30/2026 1241759909
Principal investigator 1 Mylan Technologies Inc. $4,000.00 03/06/2025 Non-covered Recipient Entity
Research Centers of America, LLC
A Phase 3, Multicenter, Open-Label, Single Arm Study of MR-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety No dispute reported 06/30/2026 1241759913
Principal investigator 1 PFIZER INC. $32,889.70 03/04/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228719749
Principal investigator 1 PFIZER INC. $176,715.47 03/04/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228723014
Principal investigator 1 ModernaTX, Inc. $29,440.80 02/27/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252985056
Principal investigator 1 ModernaTX, Inc. $9,761.40 02/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985080
Principal investigator 1 ModernaTX, Inc. $35,664.30 02/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985134
Principal investigator 1 ModernaTX, Inc. $88,250.40 02/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985166
Principal investigator 1 ModernaTX, Inc. $33,660.00 02/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985172
Principal investigator 1 ModernaTX, Inc. $2,602.80 02/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985212
Principal investigator 1 ModernaTX, Inc. $7,603.20 02/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985214
Principal investigator 1 ModernaTX, Inc. $4,606.60 02/27/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008542
Principal investigator 1 ModernaTX, Inc. $2,136.56 02/27/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008546
Principal investigator 1 ModernaTX, Inc. $1,547.00 02/26/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008564
Principal investigator 1 Alnylam Pharmaceuticals Inc. $10,000.00 02/25/2025 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215506496
Principal investigator 1 PFIZER INC. $4,359.10 02/22/2025 Non-covered Recipient Entity
Research Centers of America LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228751710
Principal investigator 1 PFIZER INC. $10.34 02/21/2025 Non-covered Recipient Entity
Research Centers of America Hollywood
A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228771191
Principal investigator 1 SANOFI PASTEUR INC. $3,670.00 02/21/2025 Non-covered Recipient Entity
Research Centers Of America
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226115654
Principal investigator 1 SANOFI PASTEUR INC. $21,568.04 02/21/2025 Non-covered Recipient Entity
Research Centers Of America
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226115660
Principal investigator 1 PFIZER INC. $815,458.80 02/19/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 OPENLABEL 2PART STUDY TO ESTIMATE SEPARATELY THE EFFECT OF ITRACONAZOLE AND FOOD ON THE PHARMACOKINETICS OF PF07258669 IN OLDER ADULT OR HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228750495
Principal investigator 1 SANOFI PASTEUR INC. $45,292.50 02/18/2025 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226095620
Principal investigator 1 PFIZER INC. $34,305.07 02/14/2025 Non-covered Recipient Entity
Research Centers of America LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228720621
Principal investigator 1 Alnylam Pharmaceuticals Inc. $955.00 02/12/2025 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215506484
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 02/12/2025 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215506489
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 02/12/2025 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215506493
Principal investigator 1 Alnylam Pharmaceuticals Inc. $10,000.00 02/12/2025 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215506501
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,481.00 02/12/2025 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215506506
Principal investigator 1 Alnylam Pharmaceuticals Inc. $846.00 02/12/2025 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215506510
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,895.00 02/12/2025 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215506514
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,675.00 02/12/2025 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215506517
Principal investigator 1 PFIZER INC. $18,000.00 02/12/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 OPENLABEL 2PART STUDY TO ESTIMATE SEPARATELY THE EFFECT OF ITRACONAZOLE AND FOOD ON THE PHARMACOKINETICS OF PF07258669 IN OLDER ADULT OR HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228758694
Principal investigator 1 ModernaTX, Inc. $1,687.50 02/05/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985042
Principal investigator 1 ModernaTX, Inc. $5,058.00 02/05/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985086
Principal investigator 1 PFIZER INC. $3,957.05 02/05/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228769336
Principal investigator 1 SANOFI PASTEUR INC. $11,320.00 02/05/2025 Non-covered Recipient Entity
Research Centers Of America
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226115618
Principal investigator 1 SANOFI PASTEUR INC. $2,000.00 02/05/2025 Non-covered Recipient Entity
Research Centers Of America
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226115623
Principal investigator 1 SANOFI PASTEUR INC. $1,750.00 02/05/2025 Non-covered Recipient Entity
Research Centers Of America
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226115629
Principal investigator 1 SANOFI PASTEUR INC. $3,670.00 02/05/2025 Non-covered Recipient Entity
Research Centers Of America
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226115635
Principal investigator 1 SANOFI PASTEUR INC. $5,000.00 02/03/2025 Non-covered Recipient Entity
Research Centers Of America
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1226115609
Principal investigator 1 ModernaTX, Inc. $6,414.12 01/30/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252985046
Principal investigator 1 ModernaTX, Inc. $31,168.80 01/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985066
Principal investigator 1 ModernaTX, Inc. $2,602.80 01/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985076
Principal investigator 1 ModernaTX, Inc. $6,930.00 01/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985078
Principal investigator 1 ModernaTX, Inc. $4,059.00 01/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985104
Principal investigator 1 ModernaTX, Inc. $6,098.40 01/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985158
Principal investigator 1 ModernaTX, Inc. $53,580.60 01/27/2025 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985202
Principal investigator 1 ModernaTX, Inc. $6,909.90 01/27/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008532
Principal investigator 1 ModernaTX, Inc. $1,521.52 01/27/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008552
Principal investigator 1 ModernaTX, Inc. $6,409.68 01/27/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253008558
Principal investigator 1 PFIZER INC. $2,079.27 01/25/2025 Non-covered Recipient Entity
Research Centers of America LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228798251
Principal investigator 1 PFIZER INC. $20,569.00 01/25/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228798951
Principal investigator 1 PFIZER INC. $17,623.39 01/24/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228802013
Principal investigator 1 PFIZER INC. $1,534.00 01/23/2025 Non-covered Recipient Entity
Res Cntrs of America HLWD
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228707165
Principal investigator 1 PFIZER INC. $1,534.00 01/23/2025 Non-covered Recipient Entity
Res Cntrs of America HLWD
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228771513
Principal investigator 1 ModernaTX, Inc. $17,973.90 01/22/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985038
Principal investigator 1 ModernaTX, Inc. $26,766.45 01/22/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985040
Principal investigator 1 SANOFI PASTEUR INC. $315,326.25 01/21/2025 Non-covered Recipient Entity
Research Centers Of America
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226115667
Principal investigator 1 SANOFI PASTEUR INC. $380.00 01/20/2025 Non-covered Recipient Entity
Research Centers Of America
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226115647
Principal investigator 1 ModernaTX, Inc. $1,308.15 01/17/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985084
Principal investigator 1 ModernaTX, Inc. $453.60 01/17/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985146
Principal investigator 1 ModernaTX, Inc. $344.30 01/17/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults No dispute reported 06/30/2026 1252985186
Principal investigator 1 PFIZER INC. $1,534.00 01/15/2025 Non-covered Recipient Entity
Res Cntrs of America HLWD
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228707167
Principal investigator 1 PFIZER INC. $1,534.00 01/15/2025 Non-covered Recipient Entity
Res Cntrs of America HLWD
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228761354
Principal investigator 1 PFIZER INC. $38,179.06 01/15/2025 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1228800416
Principal investigator 1 PFIZER INC. $2,772.36 01/15/2025 Non-covered Recipient Entity
Research Centers of America LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228801842
Principal investigator 1 ModernaTX, Inc. $68.30 01/14/2025 Non-covered Recipient Entity
Research Centers of America
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985126
Principal investigator 1 Mylan Technologies Inc. $6,000.00 01/10/2025 Non-covered Recipient Entity
Research Centers of America, LLC
A Phase 3, Multicenter, Open-Label, Single Arm Study of MR-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety No dispute reported 06/30/2026 1241759911
Principal investigator 1 SANOFI PASTEUR INC. $4,355.12 01/10/2025 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226095614
Principal investigator 1 ModernaTX, Inc. $199.56 01/06/2025 Non-covered Recipient Entity
Research Centers of America
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252985130
Principal investigator 1 ABBVIE INC. $14,700.00 01/03/2025 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LL
Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson s Disease No dispute reported 06/30/2026 1202436653
Principal investigator 1 Boehringer Ingelheim International GmbH $1,200.00 01/02/2025 Non-covered Recipient Entity
Research Centers Of America
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220663346
Principal investigator 1 Boehringer Ingelheim International GmbH $1,750.00 01/02/2025 Non-covered Recipient Entity
Research Centers Of America
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220663348
Principal investigator 1 Boehringer Ingelheim International GmbH $375.00 01/02/2025 Non-covered Recipient Entity
Research Centers Of America
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1220663350